Clinical trials
Solid Tumors (Phase 1) clinical trials
Below are recruiting solid tumors (phase 1) clinical trials, each written for real people, not researchers. We’re tracking 525 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Tucson, ArizonaAges 18 years+ - NCT05923008RecruitingPhase 1/Phase 2
Study of IBI130 for advanced solid tumors
This trial tests IBI130 in people with unresectable, locally advanced, or metastatic solid tumors (cancers that can’t be fully removed by surgery or have spread). It may help find whether the drug is safe and can work against these cancers.
Birtinya, QueenslandAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Fountain Valley, CaliforniaAges 18 years+ - NCT05941507RecruitingPhase 1/Phase 2
TROP2 antibody drug with anti–PD-1 for advanced solid tumors
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT05970016RecruitingPhase 1/Phase 2
Study for advanced solid cancers with a DNA repair target
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
Beijing, Beijing MunicipalityAges 18–70 - NCT05981703RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT05985161RecruitingPhase 2
Selinexor for wilms tumor and other solid tumors
This trial tests a drug called selinexor for children and young adults with certain types of solid tumors (like Wilms tumor, rhabdoid tumors, MPNST, or others with specific genetic changes) that have come back or not responded to standard treatment. Participants take selinexor pills to see if it can shrink or control their cancer.
Los Angeles, CaliforniaAges 1 year+ - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06081907RecruitingPhase 1/Phase 2
IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Changsha, HunanAges 18–75 - NCT06088004RecruitingPhase 1/Phase 2
ABO2011 for advanced solid tumors (phase 1/2)
This trial tests a new investigational drug called ABO2011, which is injected directly into tumors. It is for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if the drug is safe and can help shrink or slow tumor growth.
BeijingAges 18 years+ - NCT06132828RecruitingPhase 1
Testing DR30206 for advanced or metastatic solid tumors
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06136884RecruitingPhase 1
Study of AO-252 for advanced solid tumors with or without brain metastases
This trial tests an experimental oral pill (AO-252) that targets a protein called TACC3 in advanced solid tumors, including those that have spread to the brain. It is for people whose cancer has a specific genetic change (TP53 mutation) or who have prostate cancer, and who have already tried other treatments.
Detroit, MichiganAges 18 years+ - NCT06139211RecruitingPhase 1/Phase 2
JS015 combination therapy for advanced solid tumors
This trial tests a new drug called JS015 combined with standard treatments for several advanced solid tumors. It may be an option if you have esophageal, stomach, colorectal, or pancreatic cancer that has spread and you've already had standard first-line therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06150885RecruitingPhase 1/Phase 2
Study of CAR T Cells for Solid Tumors That Have Come Back
This trial tests a new type of immune cell (CAR T) made from healthy donors to fight solid tumors that have not responded to other treatments. It may be an option for people with certain cancers that show a protein called PD-L1.
Taichung, Non-USAges 18 years+ - NCT06160752RecruitingPhase 1
TYRA-200 for advanced FGFR2-altered bile duct cancer
This trial tests an experimental drug, TYRA-200, for people with advanced bile duct cancer whose tumors have a specific FGFR2 gene change and who have already tried another FGFR inhibitor. It aims to see if the drug is safe and can shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT06208410RecruitingPhase 1/Phase 2
JS105 plus other treatments for advanced solid tumors
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Zhengzhou, HenanAges 18–75 - NCT06212076RecruitingPhase 1/Phase 2
Testing IPG1094 for advanced solid tumors
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06245330RecruitingPhase 1/Phase 2
Study of AST-001 for advanced solid tumors
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
Changchun, JinlinAges 18–70 - NCT06258408RecruitingPhase 1
BB102 for advanced solid tumors that have not responded to treatment
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
Guangzhou, GuangdongAges 18–78 - NCT06257680RecruitingPhase 1
ReT01 cell therapy for advanced solid tumors
This trial tests a new cell therapy called ReT01 for people with advanced solid tumors that have stopped responding to standard treatments. It uses your own immune cells from a tumor sample to fight the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06265727RecruitingPhase 1/Phase 2
Study of CRB-701 for solid tumors with nectin-4
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
Birmingham, AlabamaAges 18 years+
Hear when a new Solid Tumors (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumors (phase 1)?
- Yes. Clin2 currently lists 525 recruiting solid tumors (phase 1) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumors (phase 1) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumors (phase 1) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.